BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 23423920)

  • 1. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
    Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
    Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography in staging early lung cancer: a randomized trial.
    Maziak DE; Darling GE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Miller JD; Gu CS; Cline KJ; Evans WK; Levine MN
    Ann Intern Med; 2009 Aug; 151(4):221-8, W-48. PubMed ID: 19581636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer.
    Parry PV; Engh JA
    Neurosurgery; 2013 Dec; 73(6):N11-3. PubMed ID: 24257336
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
    Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP
    Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer.
    Usuda K; Sagawa M; Maeda S; Motono N; Tanaka M; Machida Y; Matoba TM; Watanabe N; Tonami H; Ueda Y; Uramoto H
    Asian Pac J Cancer Prev; 2016; 17(6):2775-80. PubMed ID: 27356689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer?
    Palomar Muñoz A; García Vicente AM; Bellón Guardia ME; González García B; Talavera Rubio MP; Pilkington Woll JP; Núñez García A; Poblete García VM; Cordero García JM; Soriano Castrejón A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):124-9. PubMed ID: 21722995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?
    Hendriks LE; Bootsma GP; de Ruysscher DK; Scheppers NA; Hofman PA; Brans BT; Dingemans AM
    Lung Cancer; 2013 Jun; 80(3):293-7. PubMed ID: 23518381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary?
    Cho H; Lee HY; Kim J; Kim HK; Choi JY; Um SW; Lee KS
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):514-20. PubMed ID: 26189165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.